COVİD-19 (SARS Cov-2) Tedavisi

Öz

Korona virüs aralık 2019’un sonu itibari ile tüm dünyada yaygınlaşmış ve Mart 2020’den sonra ülkemizde de yaygın görülmeye başlamıştır. Tedavide uygulanan antiviral ilaçlardan sitokin reseptör antagonistlerine kadar çok geniş bir yelpazededir. Burada ayaktan hasta bakımındaki tedavi önerileri ile birlikte yoğun bakımdaki kritik hasta bakımı önerileri de yer almaktadır.

Anahtar Kelimeler

• covid-19,tedavi,yatan ve kritik hasta bakımı

COVID-19 (SARS Cov-2) Treatment

Öz

Corona virus has become widespread all over the world as of the end of December 2019 and it has started to be seen in our country after March 2020. It is in a wide range from antiviral drugs used in treatment to cytokine receptor antagonists. Here, along with treatment recommendations in outpatient care, critical patient care recommendations in intensive care are also included.

Anahtar Kelimeler

• Covid 19,treatment,outpatient,inpatient and critical patient care

Kaynakça

1. 1. Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020. Epub ahead of print Feb 6.
2. 2. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus disease 2019. J Clin Invest 2020; Epub ahead of print Mar 27.
3. 3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;Epub ahead of print Mar 13.
4. 4. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z,Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in vitro. Cell Res 2020; 30(3):269‐271.
5. 5. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2). Clin Infect Dis 2020; Epub ahead of print Mar 9.
6. 6. Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label nonrandomized clinical trial. International Journal of Antimicrobial Agents 2020; Epub ahead of print Mar 20.
7. 7. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al.Treatment with Lopinavir/Ritonavir or Interferon‐ß1b Improves Outcome of MERS‐CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis 2015;212(12):1904‐1913.
8. 8. Vincent Madelain V, Mentré F,Baize S, Anglaret X, Laouénan C. Et all. Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials. CPT Pharmacometrics Syst Pharmacol. 2020 Mar 20. doi: 10.1002/psp4.12510.

9. 9. Zumla, A. et al. Coronaviruses — drug discovery and therapeuticoptions. Nat. Rev. Drug Discov. 2016.15, 327–347
10. 10. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020 Mar 16. pii: ciaa272. doi: 10.1093/cid/ciaa272. [Epub ahead of print]
11. 11. Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.J Hematol Oncol, 11 (2018), p. 35
12. 12. Rossignol, J. F. Nitazoxanide: a first-in-class broadspectrum antiviral agent. Antiviral Res. 2014.110, 94–103.
13. 13. www.massgeneral.org/ MGH COVID19 Treatment Guideline Version 1.0.
14. 14. www.saglik.gov.tr./covid19rehber/ 12.04.2020.